Cerner partnered with Elligo Health Research and Freenome to increase access to clinical trials through its Learning Health Network, made up of 85 health systems, in order to advance early cancer detection.
The collaboration will use a research-activated network of health systems, real-world data and multiomics technology to help accelerate early cancer detection, according to a May 18 press release.
The partnership marks the first cancer screening trials available to Cerner's Learning Health Network, a group of 85 health systems across the U.S., that are working together to advance research and increase equitable access to clinical trials by contributing de-identified data.
"The clinical research Cerner will enable has the potential to advance early cancer detection so patients can seek timely treatment and improve their chances of survival," said Christy Dueck, vice president of Cerner Enviza. "Data and technology have the power to help clinicians and researchers expand therapeutic knowledge and accelerate their development and delivery, which can improve people's lives around the world."
According to the press release, trial participation aims to help members of the Learning Health Network bring innovative cancer prevention testing to the communities they serve.